A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
NCT ID: NCT05113953 Phase: PHASE2 Status: COMPLETED Enrollment: 147 Completion: 2022-08-19
Conditions
Binge-Eating Disorder
Interventions
Centanafadine, Placebo
Summary
The primary objective of this study is to assess the efficacy of 2 doses of centanafadine sustained-release (SR) (200 milligrams [mg] and 400 mg total daily dose [TDD]) compared with placebo in adults with moderate to severe binge eating disorder (BED).
Primary Outcome
Change From Baseline in Number of Binge Eating Days Per Week